Skip to content
Screener

Sutro Biopharma STRO Q4 2025 Annual earnings

Reported March 23, 2026

Revenue$11.7MBeat by $2.4M
EPS-$5.29Beat by $2.87
Revenue estimate$9.3M
EPS estimate-$8.16

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$13.6M
EPS estimate-$1.66

Financials

Q4 2025

Income statement

See full
Revenue$11.6M-21.4%
Operating income-$38.0M+41.7%
Net income-$46.8M+35.4%
EPS (diluted)-$20.78+24.0%

Balance sheet

See full
Cash & equivalents$58.1M-69.5%
Total debt$15.7M-32.3%
Total equity-$132.5M-397%
Total assets$173.8M-55.1%

Cash flow

See full
Operating cash flow-$26.4M+63.2%
Free cash flow-$26.4M+63.2%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$98.57M-35.0%
Enterprise value$56.11M+464%
P/S1×-1.5×

Profitability

See full
Operating margin-154.5%-57.8pp
Net margin-186.5%-61.4pp
FCF margin-172.9%-55.2pp

Returns & leverage

See full
Current ratio2×-0.6×

Segments

By product

See full
Ongoing Performance Related To Unsatisfied Performance Obligations$6.6M+10.3%
Materials Supply$1.8M+70.2%
Financing Component On Unearned Revenue$759.0K-31.2%
Research And Development Services$428.0K-53.6%

FAQ

When did Sutro Biopharma report Q4 2025 earnings?
Sutro Biopharma (STRO) reported Q4 2025 earnings on March 23, 2026.
What were Sutro Biopharma's Q4 2025 revenue and EPS?
Sutro Biopharma reported revenue of $11.7M and eps of $-5.29 for Q4 2025.
Did Sutro Biopharma beat estimates in Q4 2025?
Revenue beat the consensus estimate of $9.3M by $2.4M. EPS beat the consensus estimate of $-8.16 by $2.87.
How did Sutro Biopharma's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 21.3% from $14.8M a year earlier and eps declined 494.4% from $-0.89.
Where can I find Sutro Biopharma's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-119844) and the 10-K periodic report (0001193125-26-119873) directly on SEC EDGAR. The filing index links above go to sec.gov.